Abnormal glucose tolerance in transfusion-dependent β-thalassemic patients

被引:72
作者
Chern, JPS
Lin, KH
Lu, MY
Lin, DT
Lin, KS
Chen, JD
Fu, CC
机构
[1] Tao Yuan Hosp, Dept Family Med, Tao Yuan, Taiwan
[2] Natl Taiwan Univ, Coll Med, Dept Pediat, Taipei, Taiwan
关键词
D O I
10.2337/diacare.24.5.850
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - To study the prevalence of and risk factors for abnormal glucose tolerance in transfusion-dependent beta -thalassemic patients. RESEARCH DESIGN AND METHODS - A total of 89 transfusion-dependent beta -thalassemic patients were interviewed. Diabetes was previously diagnosed in 14 of them. In the remaining 75 patients, 68 participated in an oral glucose tolerance test. Potential risk factors were identified using the independent t test, chi (2) test, and Fisher's exact test. Logistic regression analysis was used to select the independent risk factors that best predicted abnormal glucose tolerance. A two-tailed P value of <0.05 was considered to be statistically significant. RESULTS - The prevalence of impaired glucose tolerance was 8.5% (7 of 82) and that of diabetes was 19.5% (Ih of 82). Presentation with diabetic ketoacidosis was 31.1% (5 of 16). The risk factors for abnormal glucose tolerance found in transfusion-dependent <beta>-thalassemic patients were serum ferritin concentration and hepatitis C infection. CONCLUSIONS - The interaction of iron overload and hepatitis C infection worsened the prognosis of thalassemic patients. Aggressive iron-chelation therapy as well as prevention and treatment of hepatitis C infection should be mandatory in managing glucose homeostasis in transfusion-dependent beta -thalassemic patients in Taiwan.
引用
收藏
页码:850 / 854
页数:5
相关论文
共 36 条
[1]  
[Anonymous], 1925, Trans Am Pediatr Soc
[2]  
Arrigo T, 1998, J PEDIATR ENDOCR MET, V11, P863
[3]   Survival and disease complications in thalassemia major [J].
Borgna-Pignatti, C ;
Rugolotto, S ;
De Stefano, P ;
Piga, A ;
Di Gregorio, F ;
Gamberini, MR ;
Sabato, V ;
Melevendi, C ;
Cappellini, MD ;
Verlato, G .
COOLEYS ANEMIA: SEVENTH SYMPOSIUM, 1998, 850 :227-231
[4]   EFFICACY OF DEFEROXAMINE IN PREVENTING COMPLICATIONS OF IRON OVERLOAD IN PATIENTS WITH THALASSEMIA MAJOR [J].
BRITTENHAM, GM ;
GRIFFITH, PM ;
NIENHUIS, AW ;
MCLAREN, CE ;
YOUNG, NS ;
TUCKER, EE ;
ALLEN, CJ ;
FARRELL, DE ;
HARRIS, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (09) :567-573
[5]   INSULIN-RESISTANCE AND HYPERINSULINEMIA IN HOMOZYGOUS BETA-THALASSEMIA [J].
CAVALLOPERIN, P ;
PACINI, G ;
CERUTTI, F ;
BESSONE, A ;
CONDO, C ;
SACCHETTI, L ;
PIGA, A ;
PAGANO, G .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1995, 44 (03) :281-286
[6]  
CHEN YC, 1994, BONE MARROW TRANSPL, V13, P705
[7]   CARBOHYDRATE-METABOLISM AND PANCREATIC ISLET-CELL FUNCTION IN THALASSEMIA MAJOR [J].
COSTIN, G ;
KOGUT, MD ;
HYMAN, C ;
ORTEGA, JA .
DIABETES, 1977, 26 (03) :230-240
[8]   INSULIN DEPENDENT DIABETES IN THALASSEMIA [J].
DESANCTIS, V ;
ZURLO, MG ;
SENESI, E ;
BOFFA, C ;
CAVALLO, L ;
DIGREGORIO, F .
ARCHIVES OF DISEASE IN CHILDHOOD, 1988, 63 (01) :58-62
[9]  
DESANCTIS V, 1995, CLIN ENDOCRINOL, V42, P581
[10]   FACTORS DETERMINING GLUCOSE-TOLERANCE IN PATIENTS WITH THALASSEMIA MAJOR [J].
DMOCHOWSKI, K ;
FINEGOOD, DT ;
FRANCOMBE, W ;
TYLER, B ;
ZINMAN, B .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 77 (02) :478-483